A slow-moving takeover battle that got hostile ended in a friendly manner on Monday as Human Genome Sciences (HGSI) agreed to be acquired by GlaxoSmithKline (GSK) for $3 billion in cash. The deal, worth $3.6 billion including debt, values HGSI at $14.25 per share, above Glaxo’s initial offer of $13 from three months ago. Human [...]